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PMetabolic Syndrome in Adolescents
Development of Age-Specific
Adolescent Metabolic Syndrome
Criteria That Are Linked to the Adult Treatment
Panel III and International Diabetes Federation Criteria
Courtney J. Jolliffe, MSC,* Ian Janssen, PHD*†
Kingston, Ontario, Canada
Objectives The study objectives were to develop age-specific adolescent metabolic syndrome (MetS) criteria that were
linked to the health-based Adult Treatment Panel III (ATP) and International Diabetes Federation (IDF) adult
criteria.
Background There has been no consistency in the criteria used to diagnose the MetS in adolescents. Studies have either
applied adult criteria or arbitrarily chosen adolescent high-risk cut-points.
Methods The adolescent (12 to 19 years old) MetS criteria developed in this study were linked to the ATP and IDF adult
criteria with LMS growth curve modeling for each MetS component (waist circumference, systolic and diastolic
blood pressure, high-density lipoprotein cholesterol, triglycerides, and glucose). Nationally representative data
from the National Health and Nutrition Examination Surveys were used to develop the growth curves.
Results The growth curves for each MetS component passed through the ATP and IDF cut-points at 20 years of age such
that adolescent cut-points were linked to the adult values. Age- and gender-specific cut-points for each MetS
component were developed that can be used to define high-risk values in 12- to 19-year-olds. The prevalence of
MetS in adolescents nearly doubled over the last decade and was 7.6% on the basis of the newly developed ATP
adolescent criteria and 9.6% on the basis of the newly developed IDF adolescent criteria.
Conclusions These new criteria should provide improved and age-appropriate approaches for diagnosing MetS among
adolescents. (J Am Coll Cardiol 2007;49:891–8) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.065A
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hhe metabolic syndrome (MetS), a constellation of cardio-
ascular (CVD) risk factors present in approximately 25% of
dult Americans (1), is a strong risk factor for atheroscle-
otic CVD and type 2 diabetes (2–4). In light of this
vidence; the National Heart, Lung, and Blood Institute
NHLBI) has recently published a scientific statement
ndicating that it is important to diagnose and treat the
etS in clinical settings (5).
Several adult MetS criteria have been developed (6–9).
he World Health Organization and European Group for
he Study of Insulin Resistance criteria include glucose
olerance, insulin resistance, and microalbuminuria compo-
ents, all of which are not routine clinical measures (6,7).
onversely, the National Cholesterol Education Program
rom the *School of Kinesiology and Health Studies, and the †Department of
ommunity Health and Epidemiology, Queen’s University, Kingston, Ontario,
anada. Funded by the Canadian Institutes of Health Research and the Ontario
raduate Scholarship program.t
Manuscript received March 22, 2006; revised manuscript received August 10, 2006,
ccepted August 30, 2006.dult Treatment Panel III (ATP) and International Dia-
etes Federation (IDF) criteria are clinically appropriate,
ecause all of the risk factor components can be easily and
outinely measured (8,9). The clinical-friendly nature of the
TP and IDF criteria has facilitated the widespread mea-
urement of the MetS in adults.
Alarmingly, CVD risk factor clustering has also been
ocumented among adolescents (10–12). The CVD risk
actor clustering in adolescents tracks into adulthood, sug-
esting that the early diagnosis of MetS might identify
dolescents at increased and premature cardiovascular risk
nd in need of risk factor management (13–15). However,
onsistent and objective MetS criteria do not exist for youth.
any different MetS criteria have been employed in ado-
escents, and the components and cut-points used to diag-
ose the MetS have varied considerably among studies
11,16–20). Furthermore, the adolescent cut-points used to
efine high-risk values have been arbitrarily chosen and
ave no health basis. For instance, some studies have used
he 90th age-specific percentile to define elevated blood
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use the 85th percentile instead?
From a clinical perspective it is
more appropriate to have cut-
points that are on the basis of
health risk, such as the adult
ATP and IDF cut-points.
The study objective was to de-
velop age-specific cut-points and
MetS criteria for adolescents that
were linked to the health-based
ATP and IDF adult criteria that
are widely employed in clinical
and research settings.
Methods
Criteria used to define MetS
in adolescents. The adolescent
MetS criteria developed in this
study were linked to the adult
ATP (5,8) and IDF (9) criteria.
The ATP defines MetS as hav-
ing at least 3 of the following:
high waist circumference (WC)
102 cm in men, 88 cm in women), high systolic blood
ressure(SBP) or diastolic blood pressure (DBP) (130/85
m Hg), low high-density lipoprotein cholesterol
HDL-C) (1.03 mmol/l in men, 1.30 mmol/l in
omen), high triglycerides (TG) (1.7 mmol/l), and high
lood glucose (5.6 mmol/l). The IDF requires the pres-
nce of a high WC (94 cm in men,80 cm in women) in
ddition to 2 of the remaining 4 components, with the
ut-points for these 4 components being identical to those
f ATP. The IDF also uses different WC cut-points on the
asis of race and country of origin (9). In this study,
owever, WC cut-points of 94 cm (men) and 80 cm
women) as recommended for Europids (people of Euro-
ean ancestry) was used for all National Health and Nutri-
ion Examination Survey (NHANES) subjects (9).
ata set and study population. The MetS component
ut-points were developed with data from the Third National
ealth and Nutrition Examination Survey (NHANES III,
988 to 1994) and the 1999 to 2000 and 2001 to 2002
HANES surveys. The NHANES are nationally represen-
ative cross-sectional surveys conducted with a stratified
ultistage probability design of the U.S. population. De-
ailed descriptions of each survey are found elsewhere (21).
ata from the 3 surveys were combined to maximize the
ample in this study. The NHANES underwent institu-
ional review board-approval by the National Center for
ealth Statistics, and consent was obtained from all partic-
pants and their parents/guardian if under the age of majority.
The analysis was limited to 12- to 20-year-old adoles-
ents who completed the home interview and mobile
Abbreviations
and Acronyms
ATP  Adult Treatment
Panel
BMI  body mass index
CVD  cardiovascular
disease
DBP  diastolic blood
pressure
HDL-C  high-density
lipoprotein cholesterol
IDF  International
Diabetes Federation
MetS  metabolic syndrome
NHANES  National Health
and Nutrition Examination
Survey
NHLBI  National Heart,
Lung, and Blood Institute
SBP  systolic blood
pressure
TG  triglycerides
WC  waist circumferencexamination center exam (21). Furthermore, analysis was
D
simited to those who had fasting measurements (6 h as per
HANES protocol) of HDL-C, TG, and glucose (note:
ubjects who did not fast were comparable to subjects who
asted for other characteristics including age, body mass
ndex [BMI], WC, and blood pressure). Although WC and
lood pressure were measured in every participant, analyses
ere limited to those who fasted in order to obtain similarly
atched groups for each MetS component. This resulted in
,921 male and 3,146 female participants.
easurement of the MetS components. The SBP and
BP were recorded as the average of 3 or 4 measurements with
mercury sphygmomanometer and standard protocols (21).
he WC was measured to the nearest 0.1 cm at the level of the
liac crest with standard protocols (21,22).
Lipoproteins were analyzed at the Johns Hopkins Lipopro-
ein Analytical Laboratory, and glucose was analyzed at the
niversity of Missouri-Columbia as detailed in the NHANES
aboratory Procedures Manuals (21). The HDL-C was
easured in all subjects participating in the mobile exami-
ation center exam; however, TG and glucose were only
easured in the morning subsample.
evelopment of MetS cut-points for adolescents. Age-
nd gender-specific growth curves were developed with the
ambda Mu Sigma method (23). The distribution of each
etS component were summarized by Lambda (L), Mu (M),
nd Sigma (S) curves that describe the skewness, median, and
oefficient of variance of the distribution at each age.
Each MetS component growth curve was linked to the
espective adult ATP and IDF cut-point. The first step in
reating a growth curve for a given MetS component
nvolved defining the z-score (or percentile) that corre-
ponded to the adult cut-point at 20 years of age with the
ollowing equation:
etS Component Values forale and Female P rticipants
Table 1 MetS Component Values forMale and Female Participants
n Mean (SD)
WC, cm
Males 2,906 79.6 (12.5)
Females 3,116 78.8 (11.7)
SBP, mm Hg
Males 2,876 111.7 (9.4)
Females 3,094 106.1 (7.9)
DBP, mm Hg
Males 2,876 62.7 (11.3)
Females 3,094 62.8 (8.9)
HDL-C, mmol/l
Males 2,833 1.22 (0.4)
Females 3,044 1.32 (0.39)
TG, mmol/l
Males 1,920 1.06 (1.3)
Females 2,089 1.04 (0.73)
Glucose, mmol/l
Males 1,921 5.15 (0.78)
Females 2,083 5.02 (1.9)BP  diastolic blood pressure; HDL-C  high-density liproprotein cholesterol; MetS  metabolic
yndrome; SBP  systolic blood pressure; TG  triglycerides; WC  waist circumference.
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here Y was the adult cut-point and L, M, and S were the
espective values at 20 years (23). The second step involved
alculating points on the growth curve at each age by
egressing the previously defined z-score through the ado-
escent distribution as follows:
point on curveM1LSz1⁄L
here L, M, and S are the respective age-specific values and z
s the z-score that corresponded to the adult cut-point (23).
hus, by defining the percentile that corresponded to the adult
ut-point and regressing it backward into adolescence, the
dolescent cut-points were linked to those of adults.
tatistical analysis. The datasets were managed in SAS
ersion 8.02 (SAS Institute, Cary, North Carolina). De-
criptive and chi-square analyses were performed with Stata
ersion 7.0 (Stata Corp., College Station, Texas), which
ccounted for the weighted and clustered nature of the
Figure 1 Metabolic Syndrome Component Growth Curves for M
Cut-points at age 20 correspond to the Adult Treatment Panel (ATP III) and Interna
cut-points. To convert high-density lipoprotein (HDL)-cholesterol to mg/dl, multiplyHANES sample. Stata and other survey statistical pack-
ges do not have the capability of creating the smoothed
rowth curves needed for the present study, and subse-
uently we used the LMS Pro version 1.16 (Institute of
hild Health, London). The LMS software took into
onsideration the weighting of the NHANES survey but
as not able to account for the clustered nature of the
urvey. Further discussion concerning this limitation and
resenting a more extensive description of the samples and
eighting methodology can be found in the Appendix.
esults
able 1 lists the mean values of the MetS components and
he number of subjects used to develop each growth curve.
he growth curves corresponding to the MetS cut-points
or WC (ATP and IDF), blood pressure, HDL-C, and TG
re illustrated in Figures 1 and 2 for males and females,
espectively. Fasting glucose is not illustrated in the figures,
ecause it remained constant (at 5.6 mmol/l or 100 mg/dl)
Diabetes Federation (IDF) adult
67. To convert triglycerides to mg/dl, multiply by 88.5.ales
tional
by 38.
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Adolescent Metabolic Syndrome Criteria February 27, 2007:891–8rom 12 to 20 years. Therefore, a glucose cut-point of 5.6
mol/l can be used at all ages during adolescence. As an
lternative to the growth curves, Tables 2 and 3 list the
ut-points in 1-year increments for each MetS component.
ach cut-point reflects the midpoint of a given year (i.e.,
ut-point for age 12 represents 12.5 years) and can be
pplied to all individuals within the 1-year age range (i.e.,
2.0 to 12.9 years).
Two WC curves were developed to reflect the different
dult ATP and IDF cut-points. The ATP and IDF curves
epresented the 92nd and 83rd percentiles for males (Fig.
A) and the 72nd and 50th percentiles for females (Fig.
A), respectively. The adult IDF MetS criteria indicates
hat a high WC can be assumed for those with a BMI 30
g/m2 (9). Thus, age- and gender-specific adolescent BMI
ut-points linked to a BMI of 30 kg/m2 were also created as
hown in Figure 3 and Table 4.
The SBP and DBP curves were linked to the adult ATP
nd IDF cut-points such that the curves pass though 130
Figure 2 Metabolic Syndrome Component Growth Curves for Fe
Cut-points at age 20 correspond to the ATP III and IDF adult cut-points. To convert
to mg/dl, multiply by 38.67. To convert triglycerides to mg/dl, multiply by 88.5. Abnd 85 mm Hg at 20.0 years of age (Figs. 1B and 2B). The pale and female curves followed similar trajectories. The
BP curves represented the 92nd and 93rd percentiles for
ales and females, respectively, whereas the DBP curves
epresented the 97th and 99th percentiles.
Whereas the HDL-C cut-points for males declined
lightly until age 16 (Fig. 1C), the female cut-points
ncreased marginally after age 15 (Fig. 2C). The curves were
inked to the adult cut-points (1.03 mmol/l for males, 1.30
mol/l for females) and represented the 26th and 43rd
ercentiles, respectively.
The male (Fig. 1D) and female (Fig. 2D) TG curves
ollowed different trajectories. Whereas the male curve in-
reased with age in a linear manner, the female curve
eclined during early adolescence before increasing to ap-
roach adult concentrations. The TG curves represent the
9th percentile for both genders.
The prevalences of MetS (in NHANES 1999 to 2002) in
dolescents by gender, age, and race with the 2 criteria
eveloped in this study are presented in Table 5. The
s
holesterol
tions as in Figure 1.male
HDL-c
breviarevalence of MetS in the total sample was 7.6% according
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February 27, 2007:891–8 Adolescent Metabolic Syndrome Criteriao the adolescent ATP criteria and 9.6% according to the
dolescent IDF criteria. Prevalences did not differ by gender
r age (p  0.2). However, the prevalence of IDF-MetS
as lower in non-Hispanic blacks than non-Hispanic
hites and Hispanics (p 0.05). Changes in the prevalence
f MetS from NHANES III (1988 to 1994) to NHANES
999 to 2002 were also examined. The prevalence increased
rom 4.7% to 7.6% on the basis of the adolescent ATP
riteria and from 5.3% to 9.6% on the basis of the adolescent
DF criteria (p  0.01).
iscussion
he study objective was to develop adolescent MetS criteria
hat are linked to the commonly used ATP and IDF adult
riteria. Our goals were to provide age-appropriate and
ealth-based MetS component cut-points for adolescents
nd adolescent MetS definitions that could be used consis-
ently in clinical and research settings. Most clinicians will
e familiar with the growth curve approach for identifying
igh-risk values (Figs. 1 and 2), because this approach is
imilar to that currently used to monitor height, weight, and
MI growth in youth (24). Tables 1 and 2 present age-
ge-Specific MetS Cut-Points and Corresponding Percentiles for M
Table 2 Age-Specific MetS Cut-Points and Corresponding Perce
Age* (yrs)
WC (cm) BP
NCEP ATP† (92nd) IDF‡ (83rd) SBP (92nd)
12 94.2 85.1 121
13 96.2 87.0 123
14 98.0 88.9 125
15 99.5 90.5 126
16 100.6 91.8 128
17 101.4 92.7 128
18 101.8 93.4 129
19 102.0 93.8 130
20.0 102.0 94.0 130
MetS cut-point values represent the midpoint of a 1-year increment (i.e., the values for age 12 ye
2.0 to 12.9 years). †MetS defined as 3 of the 5 criteria. ‡MetS defined as having elevated WC an
hresholds presented in Table 3. §To convert HDL-C in mmol/l to mg/dl, multiply by 38.67. To con
ATP  Adult Treatment Panel; BP  blood pressure; IDF  International Diabetes Federation; N
ge-Specific MetS Cut-Points and Corresponding Percentiles for Fe
Table 3 Age-Specific MetS Cut-Points and Corresponding Perce
Age* (yrs)
WC (cm) BP
NCEP ATP† (72nd) IDF‡ (50th) SBP (93rd)
12 79.5 72.5 121
13 81.3 74.2 123
14 82.9 75.7 125
15 84.2 76.8 126
16 85.2 77.7 128
17 86.2 78.5 128
18 87.0 79.2 129
19 87.7 79.8 130
20.0 88.0 80.0 130
MetS cut-point values represent the midpoint of a 1-year increment (i.e., the values for age 12 ye
2.0 to 12.9 years). †MetS defined as 3 of the 5 criteria. ‡MetS defined as having elevated WC an
hresholds presented in Table 3. †To convert HDL-C in mmol/l to mg/dl, multiply by 38.67. To convert TG
Abbreviations as in Tables 1 and 2.pecific thresholds that are an alternative to the growth
urves. As with any newly developed classification system,
tudies are needed to validate the adolescent MetS criteria
eveloped in this study, which could be done with interme-
iate CVD and metabolic outcomes (i.e., atherosclerotic
esions, endothelial function).
In adults, MetS is a clear predictor of atherosclerotic
VD and type 2 diabetes (5), and the NHLBI has strongly
rged its diagnosis and management in the clinical setting in
dults to help reduce chronic disease risk (5). In light of the
ncreasing prevalence of obesity and other MetS indicators
n the pediatric population (25,26), it seems as urgent to
ddress this problem in this age group. There is not a
ecognized consistent method of diagnosing MetS in youth
16), and a major goal of this study was to provide criteria
hat might resolve this issue.
Although the NHLBI has emphasized the importance of
iagnosing and managing the MetS, others have argued that
he MetS is not a useful diagnostic tool (27–29). A common
rgument is that the MetS does not incur additional health
isk beyond its individual components (27,30) or beyond
lobal risk factor assessment tools such as the Framingham
s for Males
g)
HDL-C (mmol/l)§
(26th)
TG (mmol/l)§
(89th)
Glucose
(mmol/l)§DBP (97th)
76 1.13 1.44 5.6
78 1.10 1.48 5.6
79 1.07 1.52 5.6
81 1.04 1.56 5.6
82 1.03 1.59 5.6
83 1.03 1.62 5.6
84 1.03 1.65 5.6
85 1.03 1.68 5.6
85 1.03 1.70 5.6
resent the values at 12.5 years) and can be used for individuals within the 1-year age range (i.e.,
he remaining 4 criteria. Note that elevated WC can be assumed if body mass index values above
in mmol/l to mg/dl, multiply by 88.5. To convert glucose in mmol/l to mg/dl, multiply by 18.03.
National Cholesterol Education Program; other abbreviations as in Table 1.
s
s for Females
g)
HDL-C (mmol/l)§
(43rd)
TG (mmol/l)§
(89th)
Glucose
(mmol/l)§DBP (99th)
80 1.25 1.60 5.6
82 1.25 1.53 5.6
83 1.26 1.46 5.6
84 1.26 1.44 5.6
84 1.27 1.46 5.6
85 1.27 1.53 5.6
85 1.28 1.61 5.6
85 1.29 1.68 5.6
85 1.3 1.7 5.6
resent the values at 12.5 years) and can be used for individuals within the 1-year age range (i.e.,
he remaining 4 criteria. Note that elevated WC can be assumed if body mass index values aboveales
ntile
(mm H
ars rep
d 2 of tmale
ntile
(mm H
ars rep
d 2 of tin mmol/l to mg/dl, multiply by 88.5. To convert glucose in mmol/l to mg/dl, multiply by 18.03.
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Adolescent Metabolic Syndrome Criteria February 27, 2007:891–8eart Score (5,31). Furthermore, some do not consider the
etS to be a therapeutic target, given that each MetS
omponent is treated individually. The purpose of this study
as not to debate the utility of diagnosing and treating the
etS. Rather, we developed adolescent MetS classification
ystems to facilitate the comparison of results across studies
nd to provide clinicians and researchers with objective
riteria if they choose to use it as a diagnostic or research
ool in adolescents.
The MetS classification systems developed in this study
ave several other benefits. Foremost, the adolescent cut-
oints were linked to the ATP and IDF adult cut-points,
hich themselves are based on CVD and diabetes risk. This
liminates some of the arbitrariness inherent in the percen-
ile approach used in the existing youth MetS criteria and
hould provide a more accurate assessment of risk status.
econd, the new MetS cut-points reflect the fluctuations in
C, blood pressure, and plasma lipoproteins that occur
aturally with age (32–34), which should help avoid poten-
ial misclassification that is due to age-related changes.
Figure 3 Body Mass Index Growth Curves
Cut-points for males (left) and females (right) at age 20 years correspond to the
ge-Specific BMI Cut-Points (kg/m2) andorresponding Percentiles for Males and Females
Table 4 Age-Specific BMI Cut-Points (kg/m
2) and
Corresponding Percentiles for Males and Females
Age (yrs) Males (89th) Females (84th)
12 26.62 26.28
13 27.42 26.96
14 28.15 27.54
15 28.77 28.05
16 29.27 28.54
17 29.63 29.02
18 29.86 29.46
19 29.97 29.83
20 30.00 30.001MI  body mass index.With the ATP- and IDF-linked MetS criteria developed
n this study, the prevalence of MetS in U.S. adolescents in
999 to 2002 were 7.6% and 9.6%, respectively. Prevalence
stimates were similar among genders and among younger
nd older adolescents (Table 5). These results are consistent
ith some studies (17,18) and inconsistent with others
11,19,35). The problem has been that consistent adolescent
etS criteria have been unavailable, and thus MetS criteria
nd prevalence estimates vary considerably between studies.
Of interest was the racial difference in the prevalence of
etS, which was lower in non-Hispanic black adolescents
han non-Hispanic whites and Hispanics (Table 5). This
ould be explained by the more favorable lipoprotein profiles
f non-Hispanic blacks (1,36). Of further interest was the
lmost 2-fold increase in the prevalence of MetS among
ody mass index cut-point of 30 kg/m2.
revalence of MetS in 12- to 19-Year Olds byender, Age, and Race in NHANES, 1999–2002
Table 5 Prevalence of MetS in 12- to 19-Year Olds byGender, Age, and Race in NHANES, 1999–2002
Subgroup n
Prevalence of MetS, % (SE)
ATP IDF
All 1,820 7.6 (1.1) 9.6 (1.2)
Gender
Male 926 8.2 (1.5) 9.4 (1.6)
Female 894 7.0 (1.6) 9.7 (1.9)
Age
12–15 yrs 891 7.7 (1.4) 9.0 (1.4)
16–19 yrs 918 7.7 (1.3) 10.2 (1.5)
Race
Non-Hispanic white 480 8.0 (1.7) 10.2 (1.8)*
Non-Hispanic black 500 6.4 (1.3) 6.9 (1.4)
Hispanic 760 8.0 (1.1) 10.1 (0.1)*
Significantly different from non-Hispanic black (p  0.05).adult bNHANES  National Health and Nutrition Examination Survey; other abbreviations as in Tables
and 2.
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February 27, 2007:891–8 Adolescent Metabolic Syndrome Criteriadolescents from 1988 to 1994 and 1999 to 2002. This
ncrease was most likely driven by the 50% increase in
dolescent obesity during this time period (37).
An important limitation to note is the limited age span
or which the MetS classification systems were developed
12 to 19 years). Ideally we would have included the entire
ediatric age range in our analysis; however, requesting
asting blood samples from young children is rarely per-
ormed in research settings and was not performed in
ndividuals under 12 years in NHANES. Furthermore, a
easure of sexual maturation was not incorporated into the
nalysis, and thus the growth curves represent age-related
ather than maturation-related changes. Furthermore, al-
hough using cross-sectional data to develop growth curves
s a common practice, cross-sectional comparisons between
ges might not completely represent changes over time in a
iven individual, owing to individual differences in growth
elocity.
It is possible that race-specific MetS cut-points would
rovide a more accurate assessment of risk status. However,
ecause the ATP and IDF adult cut-points are not race-
pecific (exception of IDF WC cut-points) and because we
anted to link the adolescent criteria to those used in adults,
e did not develop race-specific growth curves. Another
imitation to consider is that it would have been ideal to
irectly link the adolescent cut-points to CVD and diabetes
isk. However, because CVD and type 2 diabetes are
hronic diseases, usually of late onset, it is very difficult to
stablish a direct link between adolescent risk factor values
nd disease outcomes without having an exceptionally long
ollow-up period. Finally, a variety of methods are available
or creating smoothed growth curves. There is no method
hat is clearly the best, and it is likely that a number of
ethods would have worked as well and produced results
omparable to those of the LMS method used here (38).
onclusions
his study presents the first attempt to create classification
ystems for MetS in adolescents that are linked to adult
ealth-based values. We have developed 2 MetS criteria to
eflect the adult definitions most commonly applied in the
linical and research settings. Future studies are needed to
alidate the adolescent MetS criteria developed here.
eprint requests and correspondence: Dr. Ian Janssen, School of
inesiology and Health Studies, Queen’s University, Kingston,
ntario K7L3N6, Canada. E-mail: janssen@post.queensu.ca.
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APPENDIX
or a more extensive description of the samples and weighting
ethodology, please see the online version of this article.
